Deciphering cutaneous melanoma prognosis through LDL metabolism: Single-cell transcriptomics analysis via 101 machine...

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• Cutaneous melanoma is an aggressive skin cancer with high metastatic potential.
• Existing research on melanoma genetics and molecular pathways has overlooked the role of lipids, particularly low-density lipoprotein (LDL).

Purpose of the Study:

• To investigate the intricate relationship between LDL metabolism and cutaneous melanoma.
• To elucidate how lipids influence tumor progression, immune responses, and potential therapeutic strategies in melanoma.
• To develop a predictive tool for melanoma patient outcomes based on LDL-related factors.

Main Methods:

• Utilized Gene Set Enrichment Analysis (GSEA) to identify LDL metabolism genes.
• Analyzed single-cell and bulk RNA sequencing data (GSE215120, TCGA, GSE19234, GSE22153, GSE65904).
• Developed an LDL-related signature (LRS) using machine learning algorithms.
• Validated the function of PPP2R1A in melanoma cell lines (A375, WM-115).

Main Results:

• Demonstrated significant heterogeneity of LDL across different cell types via single-cell analysis.
• Constructed a novel LRS capable of assessing prognosis, immunity, and mutation status in cutaneous melanoma patients.
• Confirmed the functional importance of PPP2R1A, a key gene within the LRS, through experimental validation.

Conclusions:

• Low-density lipoprotein (LDL) plays a critical role in the cutaneous melanoma microenvironment.
• The developed LRS is a promising tool for predicting patient prognosis and guiding therapeutic decisions in cutaneous melanoma.
• Further research into lipid metabolism pathways offers potential for novel melanoma treatment strategies.